Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

@article{Weber2007LenalidomidePD,
  title={Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.},
  author={DonnaM. Weber and Christine Chen and Rub{\'e}n Niesvizky and Miles Wang and Andrew J. Belch and Edward A. Stadtmauer and David Siegel and Ivan Borrello and S Vincent Rajkumar and Asher Alban Chanan-Khan and Sagar Lonial and Zhinuan Yu and John Patin and Marta Olesnyckyj and Jerome Bernard Zeldis and Robert D. Knight},
  journal={The New England journal of medicine},
  year={2007},
  volume={357 21},
  pages={
          2133-42
        }
}
BACKGROUND Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma. METHODS Patients in the United States and Canada who had received at least one previous therapy for multiple myeloma but who required additional treatment were randomly assigned to receive either 25 mg of lenalidomide or placebo on days 1 to 21 of a 28-day cycle. Both groups also received 40 mg of oral… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 557 CITATIONS

FILTER CITATIONS BY YEAR

2005
2019

CITATION STATISTICS

  • 49 Highly Influenced Citations

  • Averaged 40 Citations per year over the last 3 years

Similar Papers

Loading similar papers…